Eli Lilly and Company
LLY
$1122.50
-0.61%
Eli Lilly and Company is a global pharmaceutical leader focused on developing and commercializing medicines across key therapeutic areas including cardiometabolic health, immunology, neuroscience, and oncology. The company is a dominant market leader, particularly renowned for its blockbuster GLP-1 drugs for diabetes and obesity, such as Mounjaro and Zepbound, which have established it as a central player in one of the most lucrative and rapidly expanding markets in healthcare. The current investor narrative is intensely focused on its competitive positioning in the weight-loss drug market, driven by recent positive Phase 3 data for its next-generation candidate retatrutide, while simultaneously navigating emerging competitive threats and strategic acquisitions to diversify its long-term growth pipeline beyond its current blockbusters.…
LLY
Eli Lilly and Company
$1122.50
Related headlines
Investment Opinion: Should I buy LLY Today?
Rating & Thesis: Hold. While Eli Lilly possesses a best-in-class growth profile and pipeline, its extreme valuation near all-time highs and emerging competitive threats create a balanced risk/reward profile, warranting caution despite the bullish analyst consensus.
Supporting Evidence: The recommendation is anchored by four key data points: 1) The forward P/E of 25.5x represents a significant premium to large-cap pharma peers, demanding flawless execution. 2) Revenue growth of 42.6% YoY is exceptional but may face headwinds. 3) Profitability is robust with net margin expansion to 34.4% and an ROE of 77.78%. 4) The stock trades at 96% of its 52-week range, indicating limited near-term upside before hitting technical resistance at $1182.73.
Risks & Conditions: The two biggest risks are valuation multiple contraction and competitive erosion. This Hold rating would upgrade to a Buy if the forward P/E compressed toward 20x on a market pullback without a deterioration in the growth narrative, or if competitive threats from Pfizer/Novo Nordisk demonstrably fail to materialize. It would downgrade to a Sell if quarterly revenue growth decelerates below 25% YoY or if gross margins contract significantly from the current 85%. Relative to its own hyper-growth and industry position, the stock is fairly valued to slightly overvalued, pricing in tremendous success but leaving minimal margin for error.
Sign up to view all
LLY 12-Month Price Forecast
The outlook is balanced between a powerful fundamental growth engine and significant valuation/competitive headwinds. The base case (50% probability) of consolidation is most likely, as the market awaits evidence that current growth rates are sustainable against new rivals. The stance is neutral because the risk of multiple compression in a competitive or higher-rate environment offsets the stellar operational performance. Confidence is medium due to the high uncertainty around competitor launch trajectories. The stance would upgrade to bullish on a pullback to the $900-$950 range (aligning with recent support) or downgrade to bearish if quarterly revenue growth decelerates by more than 10 percentage points.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1459.25 and implied upside of +30.0% versus the current price.
Average Target
$1459.25
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$898 - $1459
Analyst target range
Eli Lilly is covered by 11 analysts, and the institutional sentiment is overwhelmingly bullish, as evidenced by recent actions from major firms like JP Morgan, Morgan Stanley, and Deutsche Bank maintaining 'Buy' or 'Overweight' ratings. The consensus recommendation is a 'Buy', with an average target price derived from estimated EPS of $63.81, though a specific dollar target is not provided in the data. The high level of coverage and consistent bullish stance reflects the stock's status as a large-cap, institutionally-favored growth story. The target range, implied by estimated EPS, shows a low of $59.56 and a high of $69.54, representing a spread of approximately 17% from low to high. The high target likely assumes continued blockbuster commercial success for Mounjaro/Zepbound, successful launches of next-generation drugs like retatrutide, and sustained premium valuation multiples. The low target likely factors in risks such as increased competition (e.g., from Pfizer's pipeline), pricing pressure, or clinical setbacks. The relatively tight spread, given the stock's high valuation, indicates strong analyst conviction in the base-case growth trajectory, though the recent 'Reduce' rating from HSBC highlights that concerns about valuation and competition do exist.
Bulls vs Bears: LLY Investment Factors
The bull case, centered on explosive fundamental growth and pipeline dominance, currently holds stronger evidence, as reflected in the stock's 39.5% one-year outperformance and robust analyst sentiment. However, the bear case presents formidable risks, primarily around valuation and competition. The single most important tension in the investment debate is whether Lilly's hyper-growth (42.6% YoY revenue increase) can be sustained long enough to justify its extreme valuation premium (forward P/E of 25.5x vs. industry peers), or if intensifying competition from Pfizer and Novo Nordisk will inevitably compress both growth and multiples. The resolution of this tension will dictate the stock's trajectory over the next 12-24 months.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue surged 42.6% YoY to $19.29 billion, driven by blockbuster GLP-1 drugs. This accelerating growth, from a base of $13.53 billion a year ago, demonstrates the company's capture of a massive, high-demand market.
- Best-in-Class Pipeline Momentum: Recent positive Phase 3 data for next-generation drug retatrutide solidifies Lilly's leadership in the obesity market. This clinical success, highlighted in recent news, provides a multi-year growth runway beyond current blockbusters Mounjaro and Zepbound.
- Net margin expanded to 34.4% in Q4 2025 from 32.6% a year prior, with gross margin reaching 85.05%. This demonstrates powerful operating leverage and premium pricing power, translating hyper-growth into substantial earnings, evidenced by a staggering 77.78% ROE.
- Strong Free Cash Flow Generation: The company generated $8.97 billion in TTM free cash flow, providing ample internal funding for R&D, capacity expansion, and strategic acquisitions. This robust cash generation supports its elevated debt-to-equity ratio of 1.60.
Bearish
- Extreme Valuation Premium: Trading at a trailing P/E of 46.76x and a forward P/E of 25.5x, LLY commands a significant premium to large-cap pharma peers. This leaves little room for error; any growth deceleration could trigger severe multiple compression.
- Intensifying Competitive Threats: Recent news highlights emerging competition from Pfizer's monthly-injection weight-loss drug and Novo Nordisk's successful Wegovy pill. This threatens Lilly's market dominance and long-term pricing power in its core growth segment.
- Revenue Concentration & Pipeline Dependency: Growth is overwhelmingly reliant on the Cardiometabolic segment ($13.18B in Q4). The long-term strategy depends on successful launches of next-gen drugs like retatrutide and diversification into new areas like infectious diseases, which carries execution risk.
- Technical Overextension Near All-Time High: The stock trades at 96% of its 52-week range ($623.78 to $1182.73), just below its all-time high. This suggests momentum is stretched, increasing vulnerability to a pullback, as seen in the recent -23.64% drawdown from peak.
LLY Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a 1-year price change of +39.53%, significantly outperforming the broader market. As of the latest close at $1133, the price is trading at approximately 96% of its 52-week range ($623.78 to $1182.73), positioning it near all-time highs, which signals strong momentum but also raises concerns about potential overextension. The stock's beta of 0.517 indicates it has been approximately 48% less volatile than the SPY over the past year, which is atypical for a high-growth name and suggests its moves have been more driven by fundamental news than broad market swings. Recent short-term momentum is robust and accelerating, with a 1-month gain of +11.54% and a 3-month gain of +15.02%, both handily outpacing the SPY's returns of -0.08% and +12.0%, respectively. This recent strength, following a period of consolidation and a drawdown of -23.64% from its peak earlier in the year, suggests a powerful resumption of the primary uptrend, likely fueled by positive clinical trial catalysts. The divergence from the market's weaker 1-month performance underscores the stock's idiosyncratic, news-driven nature. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $1182.73 and major support at the 52-week low of $623.78. A decisive breakout above resistance would confirm the bullish thesis and potentially open the path for further gains, while a failure could lead to a retest of the recent consolidation zone around $900. The stock's low beta of 0.517 implies lower systemic risk for position sizing, but investors should note that its volatility is often event-driven, related to clinical data and competitive developments, rather than general market movements.
Beta
0.52
0.52x market volatility
Max Drawdown
-23.6%
Largest decline past year
52-Week Range
$624-$1183
Price range past year
Annual Return
+39.0%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | +11.7% | +1.5% |
| 3m | +22.3% | +13.4% |
| 6m | +6.2% | +10.9% |
| 1y | +39.0% | +24.5% |
| ytd | +3.9% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Eli Lilly's revenue trajectory is exceptionally strong, with Q4 2025 revenue of $19.29 billion representing a staggering 42.6% year-over-year growth. This growth is accelerating sequentially from prior quarters, driven overwhelmingly by its Cardiometabolic segment, which generated $13.18 billion in the latest period. The company's product portfolio, led by Mounjaro and Zepbound, is fueling what appears to be a multi-year hyper-growth phase, with analyst consensus estimating future revenue to reach approximately $130.6 billion annually, implying sustained high growth expectations. Profitability is robust and margins are expanding significantly. The company reported Q4 2025 net income of $6.64 billion, with a net margin of 34.4% and a gross margin of 85.05%. These margins represent a substantial expansion from the year-ago quarter (Q4 2024 net margin of 32.6%, gross margin of 82.24%), reflecting the powerful operating leverage and premium pricing of its new obesity and diabetes drugs. The operating margin for the latest quarter was 45.46%, up from 42.84% a year ago, demonstrating disciplined cost management alongside explosive top-line growth. The balance sheet is leveraged but supported by immense cash generation. The debt-to-equity ratio is elevated at 1.60, reflecting investments in capacity and R&D. However, the company generated $8.97 billion in trailing twelve-month free cash flow, providing substantial internal funding for growth. Return on Equity is extraordinarily high at 77.78%, and the current ratio of 1.58 indicates adequate short-term liquidity. The strong free cash flow yield, coupled with the high ROE, suggests the company can comfortably service its debt while continuing to invest aggressively in its expansion.
Quarterly Revenue
$19.3B
2025-12
Revenue YoY Growth
+0.42%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$9.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. Eli Lilly trades at a trailing PE of 46.76x and a forward PE of 25.47x. The significant gap between trailing and forward multiples reflects the market's expectation of massive earnings growth, as current profits have not yet fully annualized the explosive revenue growth from its new blockbusters. Compared to the broader Drug Manufacturers industry, Eli Lilly's valuation commands a substantial premium. Its forward PE of 25.5x is well above typical large-cap pharma averages, which often range in the mid-teens. This premium is directly attributable to its superior growth profile; the company's revenue growth of 42.6% YoY and its dominance in the high-growth obesity/diabetes market justify a higher multiple, as investors are pricing in several years of elevated expansion and market leadership. Historically, the stock's current trailing PE of 46.76x is near the upper end of its own historical range observed over recent years, where multiples have fluctuated significantly. For instance, the PE ratio has ranged from lows around 30x to highs above 200x during periods of investment or temporary earnings compression. Trading near the top of its historical band suggests the market is pricing in near-perfect execution of its growth strategy, leaving little room for disappointment. Any stumble in growth or margin expansion could lead to significant multiple contraction.
PE
46.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -2221x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Eli Lilly's primary financial risk is its elevated valuation, not its balance sheet. The trailing P/E of 46.76x and forward P/E of 25.5x imply near-perfect execution is priced in. A stumble in revenue growth, which accelerated to 42.6% YoY in Q4 2025, or margin expansion (gross margin of 85.05%) could trigger significant multiple contraction. Operationally, the company faces concentration risk, with the Cardiometabolic segment driving the majority of growth, making it highly dependent on the continued commercial success and pricing power of Mounjaro and Zepbound amidst increasing competition.
Market & Competitive Risks: The most pressing external threat is intensifying competition in the GLP-1 market. Recent news confirms Pfizer's promising monthly-injection candidate and Novo Nordisk's successful Wegovy pill launch, which could erode Lilly's market share and long-term pricing power. Valuation compression risk is high, as the stock trades at a substantial premium to the broader Drug Manufacturers industry. Despite a low beta of 0.517, the stock's volatility is event-driven (clinical data, competitive news), exposing it to sharp downdrafts on negative developments, as seen in the 23.64% max drawdown.
Worst-Case Scenario: The worst-case scenario involves a combination of clinical setbacks for next-generation pipeline assets like retatrutide, faster-than-expected market share loss to Pfizer/Novo Nordisk competitors, and subsequent multiple compression. This could unravel the growth narrative, leading analysts to slash long-term estimates. A realistic downside could see the stock re-testing its 52-week low of $623.78, representing a potential loss of approximately -45% from the current price of $1133. A more probable severe bear case would align with the analyst low EPS target, implying a significant de-rating from current levels.
FAQ
The key risks are: 1) Valuation Risk: A high forward P/E of 25.5x makes the stock vulnerable to multiple contraction if growth slows. 2) Competitive Risk: New entrants like Pfizer's monthly injection and Novo Nordisk's pill threaten market share and pricing power. 3) Concentration Risk: Over-reliance on the Cardiometabolic segment ($13.18B in Q4) for growth. 4) Execution Risk: The long-term strategy depends on successful launches of next-gen drugs like retatrutide and new therapeutic area diversification.
The 12-month forecast presents three scenarios. The base case (50% probability) sees the stock trading between $1050 and $1180, consolidating near highs as growth moderates. The bull case (30% probability) targets $1182 to $1300 on successful pipeline execution and muted competition. The bear case (20% probability) sees a drop to $850-$1050 on competitive pressures and multiple compression. The base case is most likely, assuming the company maintains strong execution but faces incremental competitive headwinds that limit multiple expansion.
LLY is fairly valued to slightly overvalued based on traditional metrics but commands a premium justified by its growth profile. Its forward P/E of 25.5x is well above the large-cap pharma industry average, which is often in the mid-teens. However, this premium is supported by 42.6% YoY revenue growth and 85% gross margins, which are exceptional for its sector. The valuation implies the market expects several years of elevated growth and sustained market leadership, leaving little room for disappointment.
LLY is a high-quality company with exceptional growth, but at its current price near all-time highs, it presents a balanced risk/reward. For investors who already own it, it's a hold. For new money, it is a good buy only for those with a long-term horizon and conviction that its growth can outpace rising competition, and who are willing to wait for a better entry point during market volatility. The 25.5x forward P/E demands near-perfect execution, and the -45% potential downside to the 52-week low highlights the risk.
LLY is unequivocally a long-term investment, suitable for a minimum holding period of 3-5 years. Its low beta of 0.517 masks its event-driven volatility related to clinical data and competition. The investment thesis is based on capturing multi-year growth from the obesity/diabetes market and pipeline success, which will take time to unfold. It is not suitable for short-term trading due to its high absolute price and sensitivity to specific news flow that is difficult to predict.
